Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Safety and Efficacy of Intrathecal NTF001 Injection in ALS (NTF-ALS)

25 maggio 2026 aggiornato da: Ruijin Hospital

A Study of the Safety and Efficacy of Intrathecal NTF001 Injection in the Treatment of Amyotrophic Lateral Sclerosis

This is a single-arm, open-label, early-phase clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of intrathecal NTF001 injection, an AAV-mediated human neuron-derived neurotrophic factor gene therapy, in patients with amyotrophic lateral sclerosis (ALS).

12 patients with ALS will be enrolled. Each participant will receive a single intrathecal administration of NTF001 and will be followed for 52 weeks after treatment. The primary outcome measures include treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Secondary outcome measures include changes in the ALS Functional Rating Scale-Revised (ALSFRS-R), quality-of-life assessments, and neurological function.

This study aims to provide preliminary clinical evidence regarding the safety and potential efficacy of intrathecal NTF001 injection in patients with ALS.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a single-arm, open-label, early-phase clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of NTF001 injection in patients with amyotrophic lateral sclerosis (ALS). NTF001 is an investigational AAV-mediated gene therapy product designed to express human neuron-derived neurotrophic factor (NDNF). The investigational product will be administered once by intrathecal injection.

12 patients with ALS will be enrolled in this study. All eligible participants will receive a single intrathecal administration of NTF001 and will undergo scheduled safety and efficacy assessments during a 52-week follow-up period after treatment.

The primary objective of this study is to assess the safety and tolerability of intrathecal NTF001 injection, primarily by evaluating the occurrence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), clinically significant laboratory abnormalities, vital signs, neurological examinations, and other safety-related findings.

The secondary objective is to explore the preliminary efficacy of NTF001 in patients with ALS. Efficacy assessments will include changes in the ALS Functional Rating Scale-Revised (ALSFRS-R), quality-of-life assessments, neurological function, and other exploratory clinical indicators.

This study is expected to provide preliminary clinical evidence regarding the safety, tolerability, and potential therapeutic effects of intrathecal NTF001 injection in patients with ALS, and to support further clinical development of AAV-mediated neurotrophic factor gene therapy for ALS.

Tipo di studio

Interventistico

Iscrizione (Stimato)

12

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Cina
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200025
        • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Voluntarily participate in this study and sign the informed consent form.
  • Agree to comply with study procedures and cooperate with all study-related assessments throughout the study.
  • Male or female patients aged 18 to 65 years.
  • Meet the diagnostic and exclusion criteria for amyotrophic lateral sclerosis according to the Chinese Expert Consensus on the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis 2022 issued by the Neurology Branch of the Chinese Medical Association.
  • Have a history of amyotrophic lateral sclerosis of no more than 5 years.

Exclusion Criteria:

  • Mini-Mental State Examination (MMSE) score < 24.
  • Patient Health Questionnaire-9 (PHQ-9) score ≥ 16.
  • Abnormal liver or renal function, defined as AST or ALT > 1.5 × upper limit of normal (ULN), or serum creatinine (Cr) > 1.5 × ULN.
  • Abnormal coagulation function or current use of anticoagulants.
  • Positive infectious disease screening, including positive HBsAg or HBV-DNA, positive HCV-RNA, positive HIV test, or positive syphilis serology.
  • Currently receiving antiviral treatment for hepatitis B or hepatitis C.
  • Unstable or severe systemic diseases, including active tuberculosis, cardiovascular, respiratory, gastrointestinal, urinary, psychiatric or neurological disorders, such as epilepsy, hematological disorders, immune system diseases, or abnormal laboratory findings that, in the opinion of the investigator, make the participant unsuitable for this study.
  • Current or previous history of malignant tumor.
  • History of severe allergic reactions, allergy to contrast agents, or inability to undergo surgical anesthesia.
  • Currently participating in another clinical trial, or participation in another clinical trial within 3 months before screening.
  • Previous receipt of gene therapy before screening.
  • Receipt of stem cell therapy within 6 months before screening.
  • Use of other investigational drugs within 4 weeks before screening or within 5 half-lives of the investigational drug, whichever is longer, or use of any medication that, in the opinion of the investigator, may affect this study.
  • Receipt of a live vaccine within 2 months before screening, or any vaccination within 30 days before screening.
  • History of alcohol dependence or drug addiction, and inability to stop alcohol consumption as instructed during the study.
  • Female participants who are pregnant or breastfeeding.
  • Participants considered unsuitable for enrollment by the investigator.
  • Patients requiring ventilator-assisted ventilation.
  • Patients allergic to the investigational intervention.
  • Patients with obvious signs of dementia.
  • Patients with other psychiatric disorders that may affect disease assessment.
  • Severely obese patients, defined as BMI > 35 kg/m².

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Low-dose NTF001
Participants in this cohort will receive a single intrathecal administration of low-dose NTF001 （2E+14 vg）injection.
Genetico: NTF001 Injection
NTF001 is an investigational AAV-mediated gene therapy product designed to express human neuron-derived neurotrophic factor (NDNF). It will be administered once by intrathecal injection to patients with amyotrophic lateral sclerosis (ALS). Participants will receive NTF001 according to the assigned dose cohort and will be followed for safety, tolerability, and preliminary efficacy.
Sperimentale: High-dose NTF001
Participants in this cohort will receive a single intrathecal administration of high-dose NTF001(4-5 E+14 vg) injection after safety evaluation of the low-dose cohort.
Genetico: NTF001 Injection
NTF001 is an investigational AAV-mediated gene therapy product designed to express human neuron-derived neurotrophic factor (NDNF). It will be administered once by intrathecal injection to patients with amyotrophic lateral sclerosis (ALS). Participants will receive NTF001 according to the assigned dose cohort and will be followed for safety, tolerability, and preliminary efficacy.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events
Lasso di tempo: From administration of NTF001 through Week 52
Safety and tolerability will be assessed by evaluating the incidence, severity, seriousness, and relationship to the investigational product of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Safety assessments will also include clinical laboratory tests, vital signs, physical examinations, neurological examinations, and other clinically significant safety findings.
From administration of NTF001 through Week 52

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in ALS Functional Rating Scale-Revised Score
Lasso di tempo: Baseline through Week 52
The ALS Functional Rating Scale-Revised (ALSFRS-R) will be used to assess functional status in patients with ALS. The total score ranges from 0 to 48, with higher scores indicating better functional status.
Baseline through Week 52
Change From Baseline in ALS Quality of Life Assessment
Lasso di tempo: Baseline through Week 52
Quality of life will be assessed using an ALS-specific quality-of-life questionnaire. Changes from baseline will be evaluated during the follow-up period, with higher or lower scores interpreted according to the scoring rules of the selected questionnaire.
Baseline through Week 52
Change From Baseline in ALSAQ-40 Score
Lasso di tempo: Baseline through Week 52
The Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) will be used to assess disease-specific quality of life. The questionnaire evaluates multiple domains of daily functioning and well-being in patients with ALS, with higher scores generally indicating worse quality of life.
Baseline through Week 52
Change From Baseline in Norris Scale Score
Lasso di tempo: Baseline through Week 52
The Norris Scale will be used to assess neurological function and disease severity in patients with amyotrophic lateral sclerosis. Changes from baseline in the Norris Scale score will be evaluated during the follow-up period, with lower scores indicating greater functional impairment.
Baseline through Week 52

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Ruijin Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 aprile 2026

Completamento primario (Stimato)

31 marzo 2028

Completamento dello studio (Stimato)

31 marzo 2028

Date di iscrizione allo studio

Primo inviato

25 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

25 maggio 2026

Primo Inserito (Effettivo)

1 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • NTF-ALS

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su NTF001 Injection

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in United Arab Emirates

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi